Neuroimaging of treatment effects in developmental neuropsychiatric disorders

Steven R Pliszka, David C. Glahn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction As has been reviewed in Section 2 of this volume, neuroimaging studies are beginning to delineate those brain systems involved in a wide range of developmental psychopathology. Regions involved in a functional domain (attention, impulse control, mood regulation, etc.) are found to be altered in children with a psychiatric disorder relative to a control group. From a treatment perspective, the question is whether such differences constitute a “biomarker, ” a biological characteristic that is objectively measured and serves as an indicator of disease processes or responses to a therapeutic intervention (Frank and Hargreaves, 2003; Wise and Tracey, 2006) (see Table 21.1). Importantly, both pharmacological and psychosocial interventions can alter biomarkers. Biomarkers need not relate directly to etiology of the disease. Take for example the clinical use of a chest radiograph. A patient with pneumonia presents with fever, shortness of breath, and infiltrates on the radiograph. The pneumonia might be viral, bacterial or due to a toxic substance. The infiltrate represents the location and seriousness of the compromised lung function independent of etiology. Treatment of the underlying condition will lead to resolution of the infiltrate, thus making the radiograph valuable in monitoring treatment effects. It is likely that the first clinical uses of neuroimaging in pediatric mental disorders will parallel this example in which the utility is tied to monitoring treatment effects. Pediatric neuroimaging studies implicate many of the same brain regions in multiple disorders.

Original languageEnglish (US)
Title of host publicationNeuroimaging in Developmental Clinical Neuroscience
PublisherCambridge University Press
Pages344-364
Number of pages21
ISBN (Print)9780511757402, 9780521883573
DOIs
StatePublished - Jan 1 2009

Fingerprint

Neuroimaging
Biomarkers
Pneumonia
Pediatrics
Therapeutics
Poisons
Brain
Psychopathology
Mental Disorders
Dyspnea
Psychiatry
Fever
Thorax
Pharmacology
Lung
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pliszka, S. R., & Glahn, D. C. (2009). Neuroimaging of treatment effects in developmental neuropsychiatric disorders. In Neuroimaging in Developmental Clinical Neuroscience (pp. 344-364). Cambridge University Press. https://doi.org/10.1017/CBO9780511757402.027

Neuroimaging of treatment effects in developmental neuropsychiatric disorders. / Pliszka, Steven R; Glahn, David C.

Neuroimaging in Developmental Clinical Neuroscience. Cambridge University Press, 2009. p. 344-364.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pliszka, SR & Glahn, DC 2009, Neuroimaging of treatment effects in developmental neuropsychiatric disorders. in Neuroimaging in Developmental Clinical Neuroscience. Cambridge University Press, pp. 344-364. https://doi.org/10.1017/CBO9780511757402.027
Pliszka SR, Glahn DC. Neuroimaging of treatment effects in developmental neuropsychiatric disorders. In Neuroimaging in Developmental Clinical Neuroscience. Cambridge University Press. 2009. p. 344-364 https://doi.org/10.1017/CBO9780511757402.027
Pliszka, Steven R ; Glahn, David C. / Neuroimaging of treatment effects in developmental neuropsychiatric disorders. Neuroimaging in Developmental Clinical Neuroscience. Cambridge University Press, 2009. pp. 344-364
@inbook{9d79ec53ab8b4af485d9d6f7da96feb1,
title = "Neuroimaging of treatment effects in developmental neuropsychiatric disorders",
abstract = "Introduction As has been reviewed in Section 2 of this volume, neuroimaging studies are beginning to delineate those brain systems involved in a wide range of developmental psychopathology. Regions involved in a functional domain (attention, impulse control, mood regulation, etc.) are found to be altered in children with a psychiatric disorder relative to a control group. From a treatment perspective, the question is whether such differences constitute a “biomarker, ” a biological characteristic that is objectively measured and serves as an indicator of disease processes or responses to a therapeutic intervention (Frank and Hargreaves, 2003; Wise and Tracey, 2006) (see Table 21.1). Importantly, both pharmacological and psychosocial interventions can alter biomarkers. Biomarkers need not relate directly to etiology of the disease. Take for example the clinical use of a chest radiograph. A patient with pneumonia presents with fever, shortness of breath, and infiltrates on the radiograph. The pneumonia might be viral, bacterial or due to a toxic substance. The infiltrate represents the location and seriousness of the compromised lung function independent of etiology. Treatment of the underlying condition will lead to resolution of the infiltrate, thus making the radiograph valuable in monitoring treatment effects. It is likely that the first clinical uses of neuroimaging in pediatric mental disorders will parallel this example in which the utility is tied to monitoring treatment effects. Pediatric neuroimaging studies implicate many of the same brain regions in multiple disorders.",
author = "Pliszka, {Steven R} and Glahn, {David C.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1017/CBO9780511757402.027",
language = "English (US)",
isbn = "9780511757402",
pages = "344--364",
booktitle = "Neuroimaging in Developmental Clinical Neuroscience",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Neuroimaging of treatment effects in developmental neuropsychiatric disorders

AU - Pliszka, Steven R

AU - Glahn, David C.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Introduction As has been reviewed in Section 2 of this volume, neuroimaging studies are beginning to delineate those brain systems involved in a wide range of developmental psychopathology. Regions involved in a functional domain (attention, impulse control, mood regulation, etc.) are found to be altered in children with a psychiatric disorder relative to a control group. From a treatment perspective, the question is whether such differences constitute a “biomarker, ” a biological characteristic that is objectively measured and serves as an indicator of disease processes or responses to a therapeutic intervention (Frank and Hargreaves, 2003; Wise and Tracey, 2006) (see Table 21.1). Importantly, both pharmacological and psychosocial interventions can alter biomarkers. Biomarkers need not relate directly to etiology of the disease. Take for example the clinical use of a chest radiograph. A patient with pneumonia presents with fever, shortness of breath, and infiltrates on the radiograph. The pneumonia might be viral, bacterial or due to a toxic substance. The infiltrate represents the location and seriousness of the compromised lung function independent of etiology. Treatment of the underlying condition will lead to resolution of the infiltrate, thus making the radiograph valuable in monitoring treatment effects. It is likely that the first clinical uses of neuroimaging in pediatric mental disorders will parallel this example in which the utility is tied to monitoring treatment effects. Pediatric neuroimaging studies implicate many of the same brain regions in multiple disorders.

AB - Introduction As has been reviewed in Section 2 of this volume, neuroimaging studies are beginning to delineate those brain systems involved in a wide range of developmental psychopathology. Regions involved in a functional domain (attention, impulse control, mood regulation, etc.) are found to be altered in children with a psychiatric disorder relative to a control group. From a treatment perspective, the question is whether such differences constitute a “biomarker, ” a biological characteristic that is objectively measured and serves as an indicator of disease processes or responses to a therapeutic intervention (Frank and Hargreaves, 2003; Wise and Tracey, 2006) (see Table 21.1). Importantly, both pharmacological and psychosocial interventions can alter biomarkers. Biomarkers need not relate directly to etiology of the disease. Take for example the clinical use of a chest radiograph. A patient with pneumonia presents with fever, shortness of breath, and infiltrates on the radiograph. The pneumonia might be viral, bacterial or due to a toxic substance. The infiltrate represents the location and seriousness of the compromised lung function independent of etiology. Treatment of the underlying condition will lead to resolution of the infiltrate, thus making the radiograph valuable in monitoring treatment effects. It is likely that the first clinical uses of neuroimaging in pediatric mental disorders will parallel this example in which the utility is tied to monitoring treatment effects. Pediatric neuroimaging studies implicate many of the same brain regions in multiple disorders.

UR - http://www.scopus.com/inward/record.url?scp=84932626531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932626531&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511757402.027

DO - 10.1017/CBO9780511757402.027

M3 - Chapter

AN - SCOPUS:84932626531

SN - 9780511757402

SN - 9780521883573

SP - 344

EP - 364

BT - Neuroimaging in Developmental Clinical Neuroscience

PB - Cambridge University Press

ER -